To the Editor:Hepatocellular carcinoma(HCC)is a prominent contributor to cancer-related mortality on a global scale.While therapeutic approaches,such as surgical resection,liver transplantation,and radiofrequency abla...To the Editor:Hepatocellular carcinoma(HCC)is a prominent contributor to cancer-related mortality on a global scale.While therapeutic approaches,such as surgical resection,liver transplantation,and radiofrequency ablation,have demonstrated effectiveness for specific patient populations,the 5-year overall survival(OS)rate in HCC is discouragingly low,estimated at only 18%.This unfavorable outcome can primarily be attributed to the high recurrence and metastasis rates.[1]Therefore,there is an urgent need for novel therapeutic strategies or targets to surmount the challenges in treating HCC.展开更多
基金supported by grants from the Capital’s Funds for Health Improvement and Research(No.2022-25121).
文摘To the Editor:Hepatocellular carcinoma(HCC)is a prominent contributor to cancer-related mortality on a global scale.While therapeutic approaches,such as surgical resection,liver transplantation,and radiofrequency ablation,have demonstrated effectiveness for specific patient populations,the 5-year overall survival(OS)rate in HCC is discouragingly low,estimated at only 18%.This unfavorable outcome can primarily be attributed to the high recurrence and metastasis rates.[1]Therefore,there is an urgent need for novel therapeutic strategies or targets to surmount the challenges in treating HCC.
